Rho-associated kinase (ROCK) has an essential role in governing cell morphology and motility, and increased ROCK activity contributes to cancer cell invasion and metastasis. Burgeoning data suggest that ROCK is also involved in the growth regulation of tumor cells. However, thus far, the molecular mechanisms responsible for ROCK-governed tumor cell growth have not been clearly elucidated. Here we showed that inhibition of ROCK kinase activity, either by a selective ROCK inhibitor Y27632 or by specific ROCK small interfering RNA (siRNA) molecules, attenuated not only motility but also the proliferation of PC3 prostate cancer cells in vitro and in vivo. Importantly, mechanistic investigation revealed that ROCK endowed cancer cells with tumorigenic capability, mainly by targeting c-Myc. ROCK could increase the transcriptional activity of c-Myc by promoting c-Myc protein stability, and ROCK inhibition reduced c-Myc-mediated expression of mRNA targets (such as HSPC111) and microRNA targets (such as miR-17-92 cluster). We provided evidence demonstrating that ROCK1 directly interacted with and phosphorylated c-Myc, resulting in stabilization of the protein and activation of its transcriptional activity. Suppression of ROCK-c-Myc downstream molecules, such as c-Myc-regulated miR-17, also impaired tumor cell growth in vitro and in vivo. In addition, c-Myc was shown to exert a positive feedback regulation on ROCK by increasing RhoA mRNA expression. Therefore, inhibition of ROCK and its stimulated signaling might prove to be a promising strategy for restraining tumor progression in prostate cancer.
INTRODUCTION
Rho-associated kinase (ROCK) is the fundamental downstream effector of the small GTPase Rho. ROCK is deregulated in a variety of cancers, such as prostate, breast and lung cancers, especially in advanced tumors, [1] [2] [3] and ROCK overexpression significantly contributes to metastasis by enhancing tumor cell invasion and motility. 2, 4 There are two similar but distinct isoforms: ROCK1 and ROCK2 (we here refer to ROCK1 and 2 as ROCK). There is an overall 65% similarity between ROCK1 and ROCK2, particularly in the catalytic kinase domain, where there is 92% identity. 5 In spite of the structural similarities, ROCK1 and ROCK2 are differentially expressed in tissues 6 and have distinct roles in different biological settings by targeting different substrates. 7, 8 ROCK1 overexpression, but not ROCK2, is often observed in cancers, and only the level of ROCK1 correlates closely with tumor progression and poor prognosis in cancer patients, including those with prostate cancer and breast cancer. [9] [10] [11] [12] In addition, a few observations also suggest the role of ROCK in regulating tumor cell growth, such as in melanoma. 13 However, the molecular bases underlying ROCKgoverned cell growth remain nearly unexplored, and the differential role of ROCK1 and ROCK2 in growth regulation still remains elusive.
Oncogene c-Myc globally reprograms cells and drives proliferation by regulating an estimated 15% of genes in the human genome. 14 Overexpression or activation of c-Myc has a decisive role in the development and progression of various cancers. 15 The phosphorylation of c-Myc at certain sites governs its activation and consequential biological functions through transcriptional activation of target genes that are necessary for cell growth, and S62 phosphorylation is necessary for its oncogenic activity. 16 Previous studies have revealed that ROCK has a crucial role in stabilizing c-Myc protein via S62 phosphorylation in RhoAtransformed kidney epithelial cells 17 and breast cancer cells. 10 However, whether ROCK directly phosphorylates c-Myc (that is, a direct physical interaction between ROCK and c-Myc) and whether there is a feedback regulation of c-Myc on ROCK remain to be determined.
In the current study, we gained insights into the regulation of ROCK on prostate cancer growth: ROCK increased the transcriptional activity of c-Myc by promoting c-Myc protein stability through phosphorylation and subsequent nuclear transportation. We also verified a novel mechanism of a positive feedback regulation of c-Myc on ROCK through transcriptional upregulation of RhoA. Inhibition of ROCK activity or downstream ROCKmediated events appears to be a promising strategy for restraining prostate tumor progression.
RESULTS

ROCK inhibition reduced cell motility and growth in vitro and in vivo
To shed light on the role of ROCK in regulating prostate cancer cell growth and progression, we inhibited ROCK kinase activity in PC3 cells using a selective inhibitor, Y27632, and specific siRNA molecules. ROCK activity was reduced by 39% and 68% upon treatment with Y27632 at 10 and 20 mM for 48 h, respectively, (Po0.05, Figure 1a ), resulting in a significant reduction in phosphorylated myosin light chain (Figure 1a ), a necessary substrate of ROCK. As myosin light chain phosphorylation increases the assembly of filamentous myosin heavy chains and enhances the binding between myosin and filamentous actin (F-actin), 5 ROCK inhibition with Y27632 led to a significant reduction in stress fiber formation as reflected by the decreased intensity of actin meshwork and condensed cellular morphology (Figure 1b) , consistent with previous observations. 10 Cell motility was restrained by 67% and 78% as assessed with cytodex beads and the transwell assay, respectively, (Po0.05, Supplementary  Figures 1A and B) . In addition, Y27632 treatment diminished cell growth of PC3 cells treated with Y27632 at 20 mM for 48 h by 24% in the MTT proliferation assay and by 30% in the BrdU incorporation assay (Po0.05, Figure 1c) . The attenuation in cell growth was also reflected in the colony formation assay: the average size of colonies in the group treated with Y27632 was significantly diminished (Po0.05, Supplementary Figure 1c) . In the in vivo experiments, all mice developed tumors at the injected sites. In agreement with the in vitro observation, ROCK inhibition in vivo exerted a robust inhibitory effect on tumor growth in mice inoculated with PC3 cells, as the growth of tumor volume over the course of time and the final tumor weight were reduced by 420% in mice treated with an intravenous injection of Y27632 compared with control mice (Po0.05, Figure 1d ). Tumor metastases were also closely examined in these mice. As shown in Supplementary  Figure 2 , the occurrence of tumor lung metastases was 30% (3 out of 10 mice) in control mice; however, no lung metastasis (0 out of 10 mice) was observed in mice treated with Y27632 (Supplementary Figure 2) . In addition, the overall health conditions of the mice administrated Y27632 were not affected. As shown in Supplementary Figure 3 , no body weight loss was found. Moreover, no abnormal activity or diets were observed. These observations suggested that the ROCK inhibitor administration at the current dose rendered no gross toxicity to mice, which was similar to previous reports. 10, 18, 19 Similar results for kinase activity, myosin light chain phosphorylation, cell motility and growth were also observed in cells transfected with ROCK-specific siRNA molecules compared with the scrambled control and blank control (Po0.05, Figures 2 and 3a) . Moreover, cell cycle progression was impeded in PC3 cells treated with Y27632. The percentage of G1 phase increased to 72% in cells treated with Y27632 at 20 mM for 48 h with a corresponding reduction in the percentages of the S phase and the G2/M phase, in comparison with 58% for the G1 phase in control cells (Figure 3b , Po0.05). It should be noted that ROCK inhibition had little influence on cell death, as Y27632 treatment did not induce apoptosis or necrosis as determined by fluorescence-activated cell sorting analysis using fluorescein isothiocyanate-annexin V and propidium iodide staining (data not shown). Taken together, these data reveal an important role for ROCK in regulating prostate cancer cell motility and proliferation. ROCK enhanced the stability and the transcriptional activity of c-Myc To elucidate the mechanisms by which ROCK modulates tumor growth, we looked into the downstream targets of ROCK. In addition to motor proteins, ROCK was suggested to target the oncogene c-Myc. 17, 20 We thus investigated the c-Myc level and the c-Myc downstream targets upon ROCK inhibition in PC3 cells. Upon attenuation of ROCK activity with siRNAs for 48 h, the level of c-Myc total protein was greatly decreased (Figure 4a ). Moreover, we used an antibody to detect phosphorylated c-Myc (p-c-Myc), which recognizes c-Myc protein singly or doubly phosphorylated at either S62 or T58, or both. Consistent with previous studies, 10,17 a significant reduction in p-c-Myc was observed in cells transfected with ROCK-siRNAs (Figure 4a ). Similar to siRNA-mediated knockdown of ROCK, a robust reduction in c-Myc and p-c-Myc was observed upon ROCK inhibition with Y27632 at 10 and 20 mM for 48 h (Figure 4b ). To substantiate this finding, we treated cells with 20 mM Y27632 at different time points, from 12 to 36 h; significantly reduced c-Myc and p-c-Myc were demonstrated after 24-h treatment (Figure 4c ). In parallel to these findings, increased kinase activity of c-Jun N-terminal kinase or apoptosis signal-regulating kinase 1 has been demonstrated to stabilize c-Myc in a S62 phosphorylationdependent manner. [21] [22] [23] These results verified an important role of ROCK-mediated S62 phosphorylation in stabilizing c-Myc.
The activated form of c-Myc (after S62 phosphorylation) appears necessary for the stability of the c-Myc protein and for c-Mycmediated cell cycle progression and tumorigenesis. 16, [24] [25] [26] S62-phosphorylated c-Myc would activate a set of target genes that facilitate cell cycle progression. 16 Upon ROCK diminishment by siRNAs or by the ROCK inhibitor, a direct transcriptional target of c-Myc, 27 HSPC111, was significantly decreased (Figures 4a and b) , confirming the regulation of ROCK on c-Myc activity. HSPC111 is overexpressed in breast cancers, and it has a role in promoting cell growth through modulation of ribosomal RNA synthesis and ribosomal assembly. 27 To substantiate the role of S62 phosphorylation in enhancing c-Myc's transcriptional activity, we mutated S62 into Ala (S62A) in a c-Myc expression construct with the site-directed mutagenesis method, and assessed the p-c-Myc level using specific antibody without cross-reactivity to non-phosphorylated c-Myc. 17 Upon S62A mutation, we observed a significant reduction in p-c-Myc level, total c-Myc level and HSPC111 level (Figure 4d ), indicating reduced protein stability and diminished ability of c-Myc in transcription because of the absence of S62 phosphorylation. Cell growth was subsequently diminished by 435% in cells with S62A mutation, as evidenced by cell number counting and the MTT assay ( Figure 4e ). Together, our results suggested that S62 phosphorylation of c-Myc promoted its protein stability and transcriptional activity, which is necessary for cell growth.
Blockade of miR-17 restrained tumor growth in vitro and in vivo In addition to mRNAs, a number of microRNAs (miRNAs) are also regulated by c-Myc. The miR-17-92 cluster is directly transcribed by c-Myc (Figure 5a ), and it has been recognized as an oncogene in human cancers. 28 Owing to c-Myc reduction resulting from ROCK inhibition, the miR-17-92 expression was greatly reduced ( Figure 5a ). As expected, an established target of miR-17, 29 the type II transforming growth factor b receptor (TbRII), was elevated because of the decrease in the miR-17 level on treatment with Y27632 ( Figure 5a ). Among the miRNAs within this cluster, miR-17, miR-19a, miR-19b-1 and miR-92a-1 were upregulated 1-1.5-fold in prostate tumors compared with normal tissues (Figures 5b and c) , suggesting a critically important role of these miRNAs in tumorigenesis of prostate cancer. miR-17 has been postulated to be involved in the regulation of cell growth, and elevated miR-17 enhances cell proliferation and tumor growth by targeting a few mRNA targets, such as TbRII. 29 The effect of miR-17 blockade on tumor growth of prostate cancer has not been investigated thus far. To this end, we blocked endogenous miR-17 with anti-miR-17 molecules in PC3 cells. As shown in Figure 5d , cell growth was significantly decreased, as reflected by the cell number counting and the MTT assay (Po0.05). In agreement with the in vitro results, tumor growth was reduced by treatment with the anti-miR-17 molecules in vivo, as evidenced by the difference in tumor volumes over the course of time between the anti-miR-17 group and the scrambled control group (Po0.05, Figure 5e ). The final tumor weight was also reduced in the anti-miR-17-treated mice compared with controls (Po0.05, data not shown). To assess the efficacy and stability of the anti-miR-17 molecules in vivo, we eventually performed western blotting to determine the level of the miR-17 target TbRII. As shown in Figure 5f , the TbRII concentration was markedly elevated by approximately twofold (Po0.05) in the tumors administrated with anti-miR-17, compared with that in tumors treated with the scrambled molecules. These results showed that anti-miR-17 molecules were a type of efficient, specific and stable silencer for endogenous miR-17 in vivo. Collectively, our data recognized an important role of miR-17 in modulating the tumor growth of prostate cancer.
ROCK directly targeted c-Myc protein
Although the regulation of c-Myc protein stability by ROCK is recognized as described above, it is unclear whether ROCK can phosphorylate c-Myc directly or through an intermediate kinase, and whether c-Myc phosphorylation by ROCK is necessary for its increased oncogenic activity. We then studied the interaction between c-Myc and ROCK with Co-immunoprecipitation and glutathione S-transferase (GST)-pulldown assays. As shown in Figure 6a , ROCK1 bound to c-Myc directly, as demonstrated by the Co-immunoprecipitation assay performed in PC3 cells, but not ROCK2. This interaction was confirmed by the GST-pulldown assay (Figure 6b ). To confirm the interaction between ROCK1 and c-Myc, we used a second cell line called the breast cancer MDA-MB-231. Similar results were also observed for MDA-MB-231 cells, as shown in Figure 6c . These results are in agreement with findings of a positive correlation of ROCK1 (but not of ROCK2) with poor prognosis and overall survival in cancer patients, and support the role of ROCK1 in modulating tumor malignancy. [9] [10] [11] To assess whether c-Myc phosphorylation by ROCK results in an enhanced oncogenic activity of c-Myc, we examined c-Myc's nuclear localization and subsequent oncogenic activity. ROCK inhibition by Y27632 significantly reduced the p-c-Myc levels not only in the cytoplasm but also in the nuclei (Figure 6d ). Immunohistochemical analysis further confirmed this alteration in p-c-Myc levels in the cytosolic and nuclear compartments ( Figure 6e ). As a result, the transcriptional activity of c-Myc was repressed as the concentration of its direct target HSPC111 was diminished ( Figure 4) ; the proliferative capability of PC3 cells was accordingly abolished (Figures 1-3) . Previous studies have demonstrated an important role of ROCK in the metastatic process by facilitating cancer cell invasion and migration. 5 Meanwhile, increasing evidence suggests that ROCK signaling is also involved in regulating tumor growth. 30 A recent study indicates that ROCK provokes tumor growth by modulating extracellular matrix deposition, remodeling and tissue stiffness. 31 In addition, previous studies suggest that ROCK activation leads to S62 phosphorylation and the consequential stabilization of c-Myc in Ras-expressing cells and breast cancer cells. 10, 17 Clinical studies reveal that c-Myc's localization in nuclei is associated with an aggressive phenotype and poor progression in B-lymphoma patients. 32, 33 In the present study, we demonstrate overall that ROCK governs tumor growth by enhancing c-Myc activity through regulation of protein stability and nuclear translocation in PC3 prostate cancer cells.
A rapid rate of c-Myc protein degradation (half-life of only 20-30 min in rapidly dividing cells) allows tight regulation on c-Myc activity. S62 phosphorylation is necessary for the stability of the c-Myc protein and its activity. 16 Previous studies demonstrate that mutation of S62 causes a twofold decrease in Gal4-c-Myc activity; 34 correspondingly, increasing S62 phosphorylation results in a 44-fold enhancement in Gal4-c-Myc activity. 35 In the current study, we demonstrate that ROCK inhibition reduces c-Myc protein stability by repressing its S62 phosphorylation and that the mutation of S62 to Ala diminishes the transcriptional activity of c-Myc. In support of this finding, S62 phosphorylation by c-Jun N-terminal kinase or apoptosis signal-regulating kinase 1 kinase also results in enhanced stability of c-Myc. [21] [22] [23] Moreover, a direct interaction between ROCK1 and c-Myc is verified by the Coimmunoprecipitation and GST-pulldown assays; however, ROCK2 might not interact with c-Myc or at least the interaction is rather weak, which could not be characterized with the techniques employed in the current study. These findings stress the important contribution of upregulated ROCK signaling to tumorigenesis by affecting c-Myc protein stability and also support a positive correlation of ROCK1 (but not ROCK2) to poor prognosis and overall survival in cancer patients. [9] [10] [11] Regarding the regulation of c-Myc protein stability, phosphorylation of c-Myc at conserved residues S62 and T58 has an important role in this process. Phosphorylation of S62 could transiently increase c-Myc stability, whereas T58 phosphorylation is closely correlated with the degradation of c-Myc. 16 In fact, the actual degradation of c-Myc is triggered by a ubiquitin-mediated process, and the ubiquitination of c-Myc is tightly dependent on its phosphorylation. 36 FBW7 (a ubiquitin E3 ligase) and Usp28 (a ubiquitin-specific protease) synergistically regulate c-Myc stability through ubiquitin-mediated degradation. [37] [38] [39] Moreover, we identified a novel positive feedback regulation of c-Myc on RhoA/ROCK signaling by directly transcribing RhoA mRNA in PC3 cells, similar to results obtained in 293T and MDA-MB-231 breast cancer cells. 20 To summarize, we decipher here a novel mechanism by which ROCK governs prostate tumor growth by enhancing c-Myc activity through the regulation of protein stability and nuclear translocation. 
MATERIALS AND METHODS
Cell culture
The human prostate cancer PC3 cell line and the breast cancer MDA-MB-231 cell line were purchased from the Shanghai Cell Bank of Type Culture Collection of the Chinese Academy of Sciences, Shanghai, China. The cells were cultured in RPMI-1640 medium with 10% fetal calf serum and penicillin-streptomycin (100 units/ml) at 37 1C with 5% CO 2 .
Animal experiments
All animal care and surgical procedures were approved by the Animal Ethics Committee at RCEES, CAS. Six-week-old immunodeficient (BALB/c nude) male mice were maintained in-house under aseptic sterile conditions. Surgeries were performed under sterile conditions and the mice received antibiotics (Gentamycin) in drinking water up to 2 weeks following the surgical procedures. For the tumor formation assay, 9.0 Â 10 5 PC3 cells were inoculated subcutaneously and bilaterally underneath the back close to the forelimbs. The cells were injected in 1:2 diluted matrigel (BD Biosciences, San Jose, CA, USA), sterile phosphate-buffered saline (PBS), using a Hamilton syringe. From the first day after cell injection, one group of mice received a selective ROCK inhibitor, Y27632 (Sigma, St Louis, MO, USA), at 4 mg/kg body weight in 100 ml PBS, injected through the tail vein (intravenous), every other day for 20 days and the control mice received only PBS. Tumor size was closely monitored with a vernier caliper and calculated according to the formula 1/2 Â L Â W Â H periodically. Mice were euthanized when tumors reached a size of 1.0 cm 3 . Tumors were separated, and a proportion of tumor tissue was fixed in 10% formaldehyde and some were stored at À 80 1C for future analyses.
To assess the inhibitory effect on tumor growth by anti-miR-17, we established a mouse model of prostate cancer with tumor tissue implantation. The experimental setup was similar to our previous method. 40 Briefly, tumors derived from PC3 cells were grown on nude mice, and tumors with a volume 41 cm 3 were separated and cut into cylindrical fragments. Tumor fragments were implanted into the back behind the right forelimbs of recipient mice. Two weeks later when tumors reached 75 mm 3 , anti-miR-17 or scrambled control RNA molecules in 50 ml PBS (2 mg/ml in PBS) were injected intratumorally every other day for 20 days. The anti-miR-17 and scrambled RNAs were synthesized as previously described. Gene expression analysis of the miR-17-92 cluster in prostate cancer A publically available data set was used to assess the miR-17-92 expression in prostate tumors. 42 The data set was generated using the Agilent microRNA V2 arrays (Agilent Technologies, Inc., Santa Clara, CA, USA) from 218 tumor samples and 149 matched normal adjacent tissues. The 
Western blot analysis
Cells were harvested into lysis buffer (Solarbio, Beijing, China) after washing with PBS. The cytoplasmic and nuclear protein contents were extracted with a ProteoJET Cytoplasmic and Nuclear Protein Extraction Kit (Thermo Fisher Scientific, Rockford, IL, USA) according to the manufacturer's instructions. Protein concentrations were determined, and equal amounts of protein (30-50 mg/sample) were subjected to 8-12% sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blot analysis as described previously. 43 Antibodies used in the current study are described in Supplementary Table 1. Immunoprecipitation Cells were lysed with the mammalian protein extraction reagent (CWBIO, Beijing, China) and incubated with 2 mg c-Myc antibody or normal mouse immunoglobulin G. Thereafter, immunoprecipitates were collected with Gamma-Bind A Sepharose beads (GE Healthcare, Uppsala, Sweden). Immunoprecipitated proteins were then subjected to sodium dodecyl sulfate-polyacrylamide gel electrophoresis and western blot analysis.
GST-pulldown assay Cell proliferation assay, colony formation assay and cell cycle assessment Cell growth was determined by the MTT assay, cell counting and the BrdU incorporation assay. In brief, PC3 cells were serum-starved overnight and then seeded at a concentration of 5.0 Â 10 4 cells/well in 100 ml culture medium with 1% FBS in the absence or presence of 10 mM or 20 mM Y27632 for 48 h, 100 mM c-Myc inhibitor 10058-F4 (Sigma) for 24 h or 1.0 mg/ml RhoA inhibitor CT04 (Cytoskeleton, Inc., Denver, CO, USA) for 6 h. Then cell growth was assessed following the manufacturer's instructions. For the colony formation assay, a single-cell suspension at a density of 5 cells/ml was prepared and inoculated into a 96-well plate at 100 ml per well. At 4 h after cell inoculation, all 96 wells were checked under a microscope and the wells with only one cell were selected for follow-up observation. Cells were cultured with 10% fetal calf serum and observed for up to 10 days. The size of colonies was recorded under a microscope.
Cell cycle progression was determined by fluorescence-activated cell sorting analysis with propidium iodide staining. PC3 cells were serum-starved overnight and then treated with 20 mM Y27632 for 48 h. After fixation with alcohol, cells were re-suspended in 1 ml of fluorochrome solution (propidium iodide at 0.05 mg/ml with 0.1 mg/ml RNAase) and incubated at 37 1C for 1 h in the dark. Thereafter, 2.0 Â 10 4 cells per sample were collected for analysis using flow cytometry (BD BioSciences). Cell cycle status was quantified using the software Flowjo 7.6 Tree Star Inc. (Ashland, OR, USA).
siRNA molecule transfection
Two sets of pre-validated siRNA molecules (Qiagen, Hilden, Germany) were used to target different regions of ROCK mRNA. PC3 cells were transfected with siRNA molecules and non-target siRNAs (the scrambled control) using siPORTTM NeoFXTM Transfection Agent (Ambion Inc., Austin, TX, USA) following the manufacturer's instructions. The experiments were performed 48 h after transfection.
ROCK kinase activity assay PC3 cells were treated with 10 or 20 mM Y27632 in culture medium with 1% FBS for 48 h. After washing with cold PBS, cells were lysed with the lysis buffer and the supernatants were obtained after centrifugation. ROCK kinase activity was determined by the ROCK Activity Assay kit (Millipore, Bedford, MA, USA) according to the manufacturer's protocol.
Confocal laser scanning microscopy analysis of cytoskeleton Cells were fixed with formaldehyde for 30 min and permeabilized with Triton X-100 in PBS for 5 min. Further, the cells were stained with 2 ml/ml fluorescein isothiocyanate-conjugated phalloidin (Molecular Probes, Eugene, OR, USA) and 0.2 ml/ml 4,6-diamidino-2-phenylindole (Molecular Probes) for 30 min in the dark after blocking with 1% fetal calf serum. Laser scanning confocal microscopy was then carried out to image the cells.
Immunofluorescent staining of p-c-Myc PC3 cells were cultured in medium containing 1% FBS with or without 20 mM Y27632 for 48 h. Thereafter, cells were fixed with formaldehyde followed by remobilization with Triton X-100. Immunofluorescence study was carried out according to the standard procedures. 43 Briefly, the cells were blocked for 1 h with 1% fetal calf serum in PBS. Cells were incubated for 2 h at room temperature with anti-p-c-Myc polyclonal antibody (1:200, Santa Cruz Biotechnology, Santa Cruz, CA, USA). The cells were then washed three times with PBS followed by incubation with dylight 594-affinipure goat antirabbit immunoglobulin G secondary antibody (EarthOx, LLC, San Francisco, CA, USA) for 1 h. After washing with PBS, the cells were examined under a Confocal laser-scanning microscope. Fluorescein isothiocyanate-conjugated phalloidin was used to label cellular F-actin, and cell nuclei were counterstained with 4,6-diamidino-2-phenylindole.
Transwell migration assay
First, 100 ml of diluted matrigel was loaded onto the upper chambers of 24-well transwells and incubated at 37 1C for 6 h. PC3 cells were treated with 10 or 20 mM Y27632 or transfected with siRNA molecules for 48 h, and cell motility was assessed with the transwell migration assay. A total of 1.0 Â 10 4 cells in 100 ml medium were seeded onto the upper chambers in 3-4 replicates under a chemotactic gradient of serum. After the cells were cultured at 37 1C overnight, the filters were removed and fixed with formaldehyde and then stained with 0.2 ml/ml 4,6-diamidino-2-phenylindole solution. The cell nuclei on the filters were visualized under a fluorescent microscope.
Bead-based cell migration assay
The in vitro migration of PC3 cells was further evaluated using Cytodex-1 beads. Briefly, 1.0 Â 10 6 cells were incubated with 60 mg beads in 6 ml culture medium overnight to coat the Cytodex-1 beads. After being washed twice with the medium, the beads with PC3 cells were cultured in medium containing 1% FBS with or without 10 or 20 mM Y27632. After 48 h, the beads were washed off and the cells that had migrated to the bottom of each well were stained with Giemsa, followed by visualization under a microscope. 
Mutagenesis
Quantification of western blots and reverse transcriptase-PCR images
The intensities of autoradiograms in western blots and PCR bands in agarose gels were quantified with Image J (NIH, http://rsbweb.nih.gov), and the quantified data of each gene/protein/miRNA were normalized to those of glyceraldehyde 3-phosphate dehydrogenase.
Statistical analysis
The two-tailed Student t-test was used to analyze the experimental data. Data are shown as mean ± s.e. Po0.05 was considered statistically significant.
